TABLE OF CONTENTS
I. EXECUTIVE SUMMARY
II. INTRODUCTION AND METHODOLOGY
III. PHYSIOLOGY OF PERIPHERAL NEUROPATHY
A. Definition of Peripheral Neuropathy
- 1. Nerve Injury
- 2. Long Duration
- 3. Abnormal Sensations
- 4. Aggravation by Physiological Processes
- 5. Cellular Mechanisms of Neuropathy
B. Definition of Peripheral Neuropathic Conditions
- 1. Diabetic Neuropathy
- 2. Peripheral Neuropathy in HIV/AIDS
- 3. Chemotherapy-Induced Neuropathy@
IV. EPIDEMIOLOGY - CURRENT AND FUTURE
A. Diabetic Neuropathy
- 1. Diabetic Neuropathy
- 2. Diabetes Prevalence
- 3. Diabetic Neuropathy Prevalence
- 4. Symptomatic Diabetic Neuropathy Prevalence
- 5. Diabetic Neuropathy Prevalence
- 6. Basis for Target Population Projections
- 7. Seven-Country Diabetic Neuropathy Population Projections
B. HIV/AIDS Neuropathy
- 1. HIV/AIDS Neuropathy
- 2. HIV/AIDS Incidence and Prevalence
- 3. AIDS Incidence and Prevalence
- 4. HIV/AIDS Neuropathy Prevalence
- 5. Basis for Target Population Projections
- 6. Seven-Country HIV/AIDS Neuropathy Population Projections
C. Chemotherapy-Induced Neuropathy
- 1. Chemotherapy-Treated Prevalence
- 2. Chemotherapy-Induced Neuropathy Prevalence
- 3. Basis for Target Population Projections
- 4. Seven-Country Chemotherapy-Induced Neuropathy Population Projections@
V. APPROACHES FOR TREATMENT OF PERIPHERAL NEUROPATHY
A. Actual Clinical Practice and Treatment Limitations
- 1. Diabetic Neuropathy Treatment
- 2. HIV/AIDS Neuropathy Treatment
- 3. Chemotherapy-Induced Neuropathy Treatment
B. Promising New Approaches
C. Future Trends
D. Drugs in Clinical Development to Treat Peripheral Neuropathy
- 1. Current Clinical Pipeline for Peripheral Neuropathy
- 1.1 Phase III, Preregistration, Registration and Launched
- 1.1.1 Aldose Reductase Inhibitors
- 1.1.2 Carnitine Acetyltransferase Stimulants
- 1.1.3 Cannabinoid Receptor Agonists
- 1.1.4 Chemoprotectants
- 1.1.5 Protein Kinase C Inhibitors
- 1.2 Phase II
- 1.2.1 Dopamine Receptor Antagonists
- 1.2.2 Nerve Growth Factor Agonists
- 1.2.3 Interleukin-6 Agonists
- 1.2.4 Prosaposin-Derived Peptide
- 1.2.5 Prostacyclin Agonists
- 1.2.6 Prostaglandin E Agonists
- 1.2.7 Undefined Mechnism
- 1.2.8 Vascular Endothelial Growth Factor (VEGF)
- 2. Promising Drugs in Preclinical Development for Peripheral Neuropathy
- 2.1 Products in Clinical Development for Other Conditions
- 2.1.1 Copolymer Surfactant
- 2.1.2 Ion Channel Inhibitors
- 2.2 Products with No Reported Clinical Development
- 3. Discontinued or Suspended Drugs@
VI. Seven-Country Peripheral Neuropathy Market Forecast
A. Forecast Methodology and Assumptions
B. Diabetic Neuropathy
- 1. Seven-Country Peripheral Neuropathy Forecast, by Class and
Country, 2007 and 2012
C. HIV / AIDS Neuropathy
- 1. Seven-Country Peripheral Neuropathy Forecast, by Condition and Country,
2007 and 2012
D. Chemotherapy-Induced Neuropathy
- 1. Seven-Country Peripheral Neuropathy Forecast, by Condition and Class,
2007 and 2012
@
VII. APPENDIX: ?SEVEN-COUNTRY PERIPHERAL NEUROPATHY MARKET FORCAST, BY
CLASS, CONDITION, AND COUNTRY
PARTIAL LIST OF TABLES & FIGURES
- Seven-Country Symptomatic Peripheral Neuropathy Patient Prevalence
Projections 2002 ? 2012
- Seven-Country Diabetic Neuropathy Population Projections
- Seven-Country HIV/AIDS Neuropathy Projections ? HIV Population
- Seven-Country HIV/AIDS Neuropathy Projections ? AIDS Population
- Seven-Country Chemotherapy-Induced Peripheral Neuropathy Population
Projections
- Summary by Phase of Drugs in Clinical Development for Peripheral
Neuropathy
- Seven-Country Prevalence of Peripheral Neuropathy, by Condition, 2002
- Seven-Country Market Forecast, by Class and Country, 2007 and 2012
- Seven-Country Market Forecast, by Condition and Country, 2007 and 2012
- Seven-Country Market Forecast, by Condition and Class, 2007 and 2012
| 
View Cart
